Acute Lymphoblastic Leukemia Market worth $3.780.3 Million by 2020

The “Acute Lymphoblastic Leukemia Therapeutics Market - (Pipeline Forecast & Market Forecast in G8 Countries) (2010 - 2020)” analyzes and studies the major market drivers, restraints, and opportunities in the U.S., Canada, U.K., France, Germany, Italy, Spain, and Japan.

Do Inquiry Before Buying @

The acute lymphocytic leukemia therapeutics market is expected to grow at a CAGR of 5.21% from 2015 to 2020. The market was dominated by drugs such as Hyper-CVAD regimen, Linker regimen, and Nucleoside metabolic inhibitors in 2010. However, by 2020; the market is expected to be dominated by Graspa (ERYtech Pharma), an innovative form of L-Asparaginase followed by Marqibo (Talon Therapeutic Inc). Pipeline drugs and increasing acute lymphocytic leukemia population globally are major factors driving the market for new drugs. A potential limiting factor in the growth of sales for acute lymphocytic leukemia drugs will be the major drugs going off-patent during the time period being forecasted.

Download PDF Brochure @

Some patients experience other symptoms, such as feeling sick, having fevers, chills, night sweats and other flu-like symptoms, or feeling fatigued. Some patients experience nausea or a feeling of fullness due to an enlarged liver and spleen; this can result in unintentional weight loss. Blasts affected by the disease may come together and become swollen in the liver or in the lymph nodes causing pain and leading to nausea.

If the leukemic cells invade the central nervous system, then neurological symptoms (notably headaches) can occur. All symptoms associated with leukemia can be attributed to other diseases. Consequently, leukemia is always diagnosed through medical tests.

From a regional approach, North America accounts for the largest acute lymphoblastic leukemia population globally. The incidence rate and mortality rate for acute lymphocytic leukemia is showing upward trend due to the increase in the aging population in most of the developed countries. Acute lymphoblastic leukemia accounts for about 20% to 25% of all childhood cancers. This type of leukemia affects children between 3 and 7 years of age.

The major players in the market include Ambit Biosciences Inc. (U.S.), ERYtech Pharma (France), Talon Therapeutic Inc. (U.S.), and Genzyme Corporation. (U.S.).

Browse Related Reports:

Leukemia Therapeutics Market (2010-2020) (Acute/Chronic Lymphocytic Leukemia & Acute/Chronic Myeloid Leukemia) Pipeline Forecast & Market Forecast in G8 Countries

Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) - Global Forecast to 2018

About MarketsandMarkets
MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals, including advanced materials, automotive and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductor and electronics, and telecommunications and IT.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Mr. Rohan
North - Dominion Plaza,
17304,Preston Road,
Suite 800, Dallas, TX 75252
Tel: +1-888-600-6441
Visit MarketsandMarkets Blog@
Connect with us on LinkedIn@